Xeris Pharmaceuticals (XERS) PT Raised to $7 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Roanna Ruiz raised the price target on Xeris Pharmaceuticals (NASDAQ: XERS) to $7.00 (from $6.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
